BamSEC and AlphaSense Join Forces
Learn More

Spark Therapeutics, Inc.

Formerly NASDAQ: ONCE
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.42
from 10-K 3 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions
12/34/56
EX-10.41
from 10-K 6 pages First Amendment to Lease
12/34/56
EX-10.3
from 10-Q 6 pages Cash Collateral Agreement
12/34/56
EX-10.1
from 10-Q 44 pages Dedicated Manufacturing and Commercial Supply Agreement
12/34/56
EX-10.1
from 10-Q 19 pages Asset Purchase Agreement by and Between Jazz Pharmaceuticals Ireland Limited and Spark Therapeutics, Inc. April 30, 2018 Asset Purchase Agreement
12/34/56
EX-10.3
from 10-Q 39 pages Spk-9001 Manufacture and Supply Agreement
12/34/56
EX-10.37
from 10-K 73 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Licensing and Commercialization Agreement by and Between Spark Therapeutics, Inc. and Novartis Pharma AG January 24, 2018
12/34/56
EX-10.36
from 10-K 46 pages Supply Agreement
12/34/56
EX-10.35
from 10-K 28 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Amendment #2 to License Agreement
12/34/56
EX-10.34
from 10-K 58 pages This Lease (“Lease”) Is Entered Into as of November 20, 2017, Between Brandywine 3025 Market, LP, a Pennsylvania Limited Partnership (“Landlord”), and Spark Therapeutics, Inc., a Delaware Corporation (“Tenant”). in Consideration of the Mutual Covenants Stated Below, and Intending to Be Legally Bound, the Parties Covenant and Agree as Follows: 1.key Defined Terms
12/34/56
EX-10.1
from 10-Q 3 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions
12/34/56
EX-10.32
from 10-K 63 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. License and Option Agreement by and Between Spark Therapeutics, Inc. and Selecta Biosciences, Inc. December 2, 2016
12/34/56
EX-10.2
from 10-Q 19 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 7 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions
12/34/56
EX-10.36
from 10-K 2 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. License Agreement Amendment
12/34/56
EX-10.35
from 10-K 101 pages Lease by and Between Wexford-Ucsc II, LP, a Delaware Limited Partnership and Spark Therapeutics, Inc., a Delaware Corporation Lease
12/34/56
EX-10.34
from 10-K 6 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Amendment No.1 to Master Research Services Agreement by and Between the Children’s Hospital of Philadelphia and Spark Therapeutics, Inc
12/34/56
EX-10.33
from 10-K 2 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. License Agreement - Amendment Three
12/34/56
EX-10.32
from 10-K 3 pages Amendment to Employment Agreement
12/34/56
EX-10.31
from 10-K 19 pages Background
12/34/56